title: Platelet count and associated morbidities in VLBW infants with pharmacologically treated patent ductus arteriosus.
abstract: OBJECTIVE
  Characterize the diagnosis of PDA and the distribution of pretreatment platelet count in pharmacologically managed PDA in infants ≤1500 g and assess the relationship of platelet count to serious morbidities.
  
  
  METHODS
  This is a retrospective, observational study. In 40 hospitals, data were collected on PDA, including pretreatment platelet count. Distribution of platelet count was examined. The association of platelet count and clinical outcomes of IVH, NEC and PDA closure prior to discharge were examined. Chi-square test was used to compare outcomes by platelet count groups.
  
  
  RESULTS
  There were 311 patients treated with medically treated PDA. Pretreatment platelet counts were categorized as 0-119 K, 120-199 K, 200-299 K, >300 K. Incidence and grade of IVH were not significantly different by platelet group. Across all groups: No IVH 62-83%, Grades 1-2 IVH 13-25%, Grades 3-4 IVH 2-13%. NEC occurred in 0-11% of all patients studied. PDA closure rate was 33-45%.
  
  
  CONCLUSIONS
  PDA closure was not significantly affected by platelet count. Platelet count was not a statistically significant factor for development of IVH and NEC in infants born <1500 g with pharmacologically treated PDA.
authors.affiliation: a Department of Pediatrics, Division of Neonatology , Los Angeles County Harbor-UCLA Medical Center , Torrance , CA , USA .|b Department of Pediatrics, Division of Neonatology , CHOC Children's Hospital Orange County , Orange , CA , USA .
authors.forename: Daniel P
authors.initials: DP
authors.lastname: Murphy
authors.affiliation: c Department of Pediatrics, Division of Neonatal & Developmental Medicine , Stanford University , Palo Alto , CA , USA .|d California Perinatal Quality Care Collaborative , Palo Alto , CA , USA .
authors.forename: Henry C
authors.initials: HC
authors.lastname: Lee
authors.affiliation: e Department of Pediatrics, Division of Neonatology , Cedars-Sinai Medical Center , Los Angeles , CA , USA , and.
authors.forename: Kurlen S E
authors.initials: KS
authors.lastname: Payton
authors.affiliation: d California Perinatal Quality Care Collaborative , Palo Alto , CA , USA .|f Department of Pediatrics, Division of Neonatology , Good Samaritan Hospital , San Jose , CA, USA.
authors.forename: Richard J
authors.initials: RJ
authors.lastname: Powers
mesh_terms: D001792:Blood Platelets / Q000187:drug effects / Q000473:pathology*; D015897:Comorbidity; D016861:Cyclooxygenase Inhibitors / Q000627:therapeutic use*; D004374:Ductus Arteriosus, Patent / Q000097:blood* / Q000150:complications / Q000188:drug therapy* / Q000453:epidemiology*; D020345:Enterocolitis, Necrotizing / Q000097:blood / Q000453:epidemiology; D006801:Humans; D052577:Infant, Extremely Low Birth Weight / Q000097:blood*; D007231:Infant, Newborn; D010976:Platelet Count; D012189:Retrospective Studies
chemical_list: D016861:Cyclooxygenase Inhibitors
keywords: COX1 inhibitor; intraventricular hemorrhage; ligation; necrotizing enterocolitis; patent ductus arteriosus; thrombocytopenia; very low birth weight